iCare - a self-directed, interactive online program to improve health and wellbeing for people living with upper gastrointestinal or hepato-pancreato-biliary cancers, and their informal carers: the study protocol for a Phase II randomised controlled trial
- Author(s)
- Livingston, PM; Winter, N; Ugalde, A; Orellana, L; Mikocka-Walus, A; Jefford, M; Zalcberg, J; Orford, N; Hutchinson, AM; Barbour, A; Kiss, N; Smithers, BM; Watson, DI; McCaffrey, N; White, V; iCare Advisory Group;
- Details
- Publication Year 2024-01-29,Volume 24,Issue #1,Page 144
- Journal Title
- BMC Cancer
- Publication Type
- Protocol
- Abstract
- BACKGROUND: Up to 70% of people diagnosed with upper gastrointestinal (GI) tract or hepato-pancreato-biliary (HPB) cancers experience substantial reductions in quality of life (QoL), including high distress levels, pain, fatigue, sleep disturbances, weight loss and difficulty swallowing. With few advocacy groups and support systems for adults with upper GI or HPB cancers (i.e. pancreas, liver, stomach, bile duct and oesophageal) and their carers, online supportive care programs may represent an alternate cost-effective mechanism to support this patient group and carers. iCare is a self-directed, interactive, online program that provides information, resources, and psychological packages to patients and their carers from the treatment phase of their condition. The inception and development of iCare has been driven by consumers, advocacy groups, government and health professionals. The aims of this study are to determine the feasibility and acceptability of iCare, examine preliminary efficacy on health-related QoL and carer burden at 3- and 6-months post enrolment, and the potential cost-effectiveness of iCare, from health and societal perspectives, for both patients and carers. METHODS AND ANALYSIS: A Phase II randomised controlled trial. Overall, 162 people with newly diagnosed upper GI or HPB cancers and 162 carers will be recruited via the Upper GI Cancer Registry, online advertisements, or hospital clinics. Patients and carers will be randomly allocated (1:1) to the iCare program or usual care. Participant assessments will be at enrolment, 3- and 6-months later. The primary outcomes are i) feasibility, measured by eligibility, recruitment, response and attrition rates, and ii) acceptability, measured by engagement with iCare (frequency of logins, time spent using iCare, and use of features over the intervention period). Secondary outcomes are patient changes in QoL and unmet needs, and carer burden, unmet needs and QoL. Linear mixed models will be fitted to obtain preliminary estimates of efficacy and variability for secondary outcomes. The economic analysis will include a cost-consequences analysis where all outcomes will be compared with costs. DISCUSSION: iCare provides a potential model of supportive care to improve QoL, unmet needs and burden of disease among people living with upper GI or HPB cancers and their carers. AUSTRALIAN AND NEW ZEALAND CLINICAL TRIALS REGISTRY: ACTRN12623001185651. This protocol reflects Version #1 26 April 2023.
- Publisher
- BioMed Central
- Keywords
- Adult; Humans; Quality of Life/psychology; Caregivers/psychology; Australia; *Upper Gastrointestinal Tract; *Neoplasms/therapy; Randomized Controlled Trials as Topic; Clinical Trials, Phase II as Topic; Bile duct; Economics of cancer; Liver; Oesophagus; Online; Pancreas; Phase II randomised controlled trial; Stomach; Supportive care; Upper GI cancers; Web-based platforms
- Department(s)
- Health Services Research
- Publisher's Version
- https://doi.org/10.1186/s12885-024-11861-2
- Open Access at Publisher's Site
https://doi.org/10.1186/s12885-024-11861-2- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-03-12 06:27:00
Last Modified: 2024-03-12 06:47:38